Table of Content


Frequent Abbreviations

1 Executive Summary

2 Introduction

3 Monocyte and Macrophage Biology

4 CAR-M Landscape Analysis
4.1 Company Evaluations
4.1.1 Corporate Overview
4.1.2 Financing
4.1.3 Partnering
4.2 CAR-M Technology Evaluations
4.2.1 Autologous CAR-M Technologies
4.2.2 Allogeneic CAR-M Technologies
4.3 Evaluation of CAR-M Pipeline, Targets and Proof-of-Concept

5 Company Profiles
5.1 Carisma Therapeutics
5.2 CellOrigin Biotech
5.3 Evotec
5.4 Fate Therapeutics
5.5 Inceptor Bio
5.6 Myeloid Therapeutics
5.7 Shoreline Biosciences
5.8 Thunder Biotech

6 Technology Profiles
6.1 ATAK CAR Monocytes
6.2 CAR-iMAC Technology
6.3 CAR-M Platform
6.4 iPSC CAR Macrophage (iMAC) Technology

7 CAR-M Cell Therapy Candidate Profiles
7.1 CT-0508
7.2 CT-0525
7.3 CT-1119
7.4 MT-101
7.5 MT-102
7.6 MT-301
7.7 MT-302

8 References
Tables in the Text